KATY MILLER: Open Payments
NPI 1487285839 · WORCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,140 in 75 payments from 15 companies in 2025. Trend: 2023 $438 · 2024 $784 · 2025 $2,140
Food & beverage: $2,140
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $475 |
| Novo Nordisk Inc | 13 | $444 |
| Insulet Corporation | 2 | $230 |
| Amgen Inc. | 12 | $219 |
| AstraZeneca Pharmaceuticals LP | 4 | $201 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $132 |
| Phathom Pharmaceuticals, Inc. | 2 | $122 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $98 |
| Astellas Pharma US Inc | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
Products named: QULIPTA, OMNIPOD, Wegovy, Ozempic, VRAYLAR, CAPLYTA, EVENITY, VOQUEZNA.
Industry payments across MA — which companies pay providers there.
